OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule
Executive Summary
Financial model isn't adequate currently, FDA Commissioner Robert Califf says, and agency may make regulatory changes to motivate sponsors.
You may also be interested in...
US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales
Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model label to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.
US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales
Agency signals assurance about making naloxone available OTC, so much so that firms with approved NDAs for Rx products should prepare for an all-nonprescription market. After offering model DFl to spur OTC switch NDAs, FDA notice about OTC assessment is second unprecedented step on its naloxone journey since opioid crisis declared a public health emergency in 2017.
OTC Naloxone NDA First Module Filed With US FDA
Module comprising clinical study reports submitted in accordance with Harm Reduction Therapeutics’ rolling review proposal accepted by FDA after the agency in July granted fast track status for the application.